Neogen Corporation NEOG is well poised to gain in the coming quarters, thanks to its continued product development efforts that enhance its existing offerings and advance its business strategy. The integration of the former 3M Food Safety business is also very promising. An unfavorable solvency position and competitive pressure remain concerns for Neogen’s operations.
The Zacks Rank #3 (Hold) stock has gained 88.5% in the past year, outperforming the industry’s 30.9% decline as well as the S&P 500 composite’s 24.4% gain.
The renowned food and animal safety product provider has a market capitalization of $1.31 billion. Neogen’s earnings yield of 3.2% is on par with the industry’s yield. The company beat on earnings in two of the trailing four quarters and missed in two, delivering an average surprise of 27.6%.
Let’s delve deeper.
Tailwinds for NEOG Stock
Product Launches: Neogen’s product development efforts focus on bringing new products to market that advance its business strategy and enhance its existing offerings. In October 2025, the company introduced Neogen MPNTray, a new extension of its Colitag Water Testing System, designed for water testing laboratories and municipalities. Other key launches include the Listeria Right Now molecular detection assay, Igenity BCHF and MDA2 Quantitative Salmonella (MDA2QSAL96).
Neogen has ongoing development projects for several new and improved diagnostic tests and other complementary products for both the Food Safety and Animal Safety markets, many of which are expected to be commercially available at various times during fiscal 2026.
3M Integration Synergy Impressive: Neogen’s 2022 merger with 3M’s Food Safety business is expected to generate significant long-term value for shareholders of the combined company. The former 3M business had built a broad global presence, with products used in more than 60 countries and a diversified revenue base of more than 100,000 end-user customers.
The combined company now has an enhanced geographic footprint and product offerings, digitization capabilities, and financial flexibility to capitalize on robust growth trends in sustainability, food safety and supply-chain integrity.
The transaction also added 3M’s flagship indicator testing brand, Petrifilm, which is now part of Neogen Culture Media. Neogen has made significant progress in integrating the former 3M Food Safety business, navigating through a complex process amid execution and macroeconomic challenges.
Image Source: Zacks Investment Research
What Concerns Neogen?
Weak Solvency: Neogen exited the third quarter of fiscal 2026 with cash and cash equivalents of $159.9 million and a significantly high total outstanding debt of $793 million. Debt to capital ratio was 27.4%, which remained unchanged from the prior-quarter levels.
Competitive Landscape Tough: Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition from competitors developing new technologies, which could adversely impact the marketability and profitability of its products.
NEOG Stock Estimate Trend
In the past 30 days, the Zacks Consensus Estimate for Neogen’s earnings for fiscal 2026 has remained constant at 29 cents.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $857.1 million, which indicates a 4.2% year-over-year decline.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical GMED, Integra LifeSciences IART and Phibro Animal Health PAHC.
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Neogen Corporation (NEOG): Free Stock Analysis Report
Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).